Free Technical Research on Versartis and Three More Biotech Equities

Stock Research Monitor: VRTX, XXII, and ABEO

LONDON, UK / ACCESSWIRE / June 5, 2018 / If you want a free Stock Review on VSAR sign up now at www.wallstequities.com/registration. On Monday, June 04, 2018, the NASDAQ Composite ended the trading session at 7,606.46, up 0.69%; the Dow Jones Industrial Average edged 0.72% higher, to finish at 24,813.69; and the S&P 500 closed at 2,746.87, slightly advancing 0.45%. Gains were broad based as seven out of nine sectors ended the day in positive. This Tuesday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Versartis Inc. (NASDAQ: VSAR), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), 22nd Century Group Inc. (NYSE AMER: XXII), and Abeona Therapeutics Inc. (NASDAQ: ABEO). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Versartis

Menlo Park, California headquartered Versartis Inc.’s stock finished Monday’s session 6.90% higher at $1.55 with a total trading volume of 8.67 million shares, which is above its three months average volume of 373.67 thousand shares. The Company’s shares have advanced 3.33% in the last month. The stock is trading below its 50-day moving average by 0.06%. Additionally, shares of Versartis, which operates as an endocrine-focused biopharmaceutical company in the US, have a Relative Strength Index (RSI) of 54.43. Get the full research report on VSAR for free by clicking below at:

www.wallstequities.com/registration/?symbol=VSAR

Vertex Pharmaceuticals

On Monday, shares in Boston, Massachusetts headquartered Vertex Pharmaceuticals Inc. recorded a trading volume of 2.57 million shares, which is above its three months average volume of 1.46 million shares. The stock ended the session 1.58% lower at $149.65. The Company’s shares have advanced 15.20% over the last twelve months. The stock is trading below its 50-day moving average by 4.64%. Moreover, shares of Vertex Pharma, which develops medicines for serious diseases, have an RSI of 37.82. Get access to our top-rated research, including the free report on VRTX at:

www.wallstequities.com/registration/?symbol=VRTX

22nd Century Group

Williamsville, New York headquartered 22nd Century Group Inc.’s shares closed the day 0.45% higher at $2.24. The stock recorded a trading volume of 1.97 million shares, which is above its three months average volume of 1.72 million shares. The Company’s shares have gained 10.89% in the last month and 60.00% over the last twelve months. The stock is trading above its 50-day moving average by 0.08%. Additionally, shares of 22nd Century, which provides technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding, have an RSI of 52.37. Click here to subscribe for a free membership which welcomes you with our report on XXII at:

www.wallstequities.com/registration/?symbol=XXII

Abeona Therapeutics

Shares in Dallas, Texas-based Abeona Therapeutics Inc. finished 11.29% lower at $15.52. The stock recorded a trading volume of 1.67 million shares, which is above its three months average volume of 1.04 million shares. The Company’s shares have advanced 190.19% over the last twelve months. The stock is trading below its 50-day moving average by 11.99%. Furthermore, shares of Abeona Therapeutics, which focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases, have an RSI of 41.42. To get free access to your research report on ABEO, sign up at:

www.wallstequities.com/registration/?symbol=ABEO

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document. ;

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 501750